Search for: "Cephalon Inc." Results 101 - 120 of 169
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
24 Mar 2010, 4:45 am
(Patent Docs) (Patent Quality Review Blog) Nuvigil (Armodafinil) – US: Patent infringement complaint filed following a Para IV certification: Cephalon, Inc. et al. v. [read post]
13 Jan 2014, 4:02 am
Take for example, the pharmaceuticals case of Cephalon Inc v Orchid Europe Ltd [2010] EWHC 2945 (Pat) [briefly noted on PatLit here] in which Floyd J (as he was) treated the issue of who is likely to suffer the most irreparable harm as the key factor in the balance of convenience assessment itself: "Balance of convenienceThere is no dispute as to the approach which I should apply. [read post]
30 Nov 2017, 8:59 pm by Brenda Fulmer
Counsel representing several Plaintiffs filed for consolidation of the actions of state, county, and municipal governments and other agencies against opiate manufacturers Purdue Pharma, Teva/Cephalon, Janssen, Endo, Actavis, and Mallinckrodt and distributors McKesson Corporation, AmerisourceBergen Corporation, and Cardinal Health, Inc. [read post]
10 Jul 2013, 12:00 am
 While synthesizing and screening compounds is considered routine experimentation, the Court noted in Cephalon, Inc. v. [read post]
10 Oct 2007, 9:15 pm
  Manufactured by Cephalon, Inc., Fentora is most commonly prescribed to treat breakthrough pain in terminal cancer patients who have already developed a tolerance to opioid pain medications. [read post]
24 Nov 2010, 12:37 am by Kelly
Use of pipeline system (IP tango) EU: Notes from EU Parliament meeting on innovation+access for medical technologies (KEI) Netherlands: District Court of The Hague declares Dutch part of Bayer’s European patent covering anti-TNF alpha human monoclonal antibodies invalid (Kluwer Patent Blog) Southeast Asia: Generic drug market picks up steam in Southeast Asia, finds Front & Sullivan (GenericsWeb) Spain: Commercial Court No 5 of Barcelona: obtaining price for generic medicament an act of… [read post]
25 Apr 2012, 1:56 pm by Jeffrey May
The FTC has another “pay-for-delay” action pending against pharmaceutical manufacturer Cephalon, Inc. for allegedly restraining competition for its branded drug, Provigil, by paying four competing firms to refrain from selling generic versions of the drug. [read post]
3 Jun 2009, 5:49 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: []   Highlights this week included: Singulair (Montelukast) – US: Merck & Co’s Singulair patent challenged on $50K bounty (Patent Baristas) (GenericsWeb)   General Docs at BIO (Panel addresses narrowing scope of biotech patents – Patent Docs), (‘Perfect storm’ super session – Patent Docs) (Biotech… [read post]